This website uses cookies to give you the best user experience. If you continue
without changing your settings we'll assume you are happy to receive all RSC cookies.
You can change your cookie settings by navigating to our Privacy and Cookies page and following the instructions. These instructions
are also obtainable from the privacy link at the bottom of any RSC page.
Renovis, Inc. (a wholly-owned subsidiary of Evotec AG), Two Corporate Drive, South San Francisco, USA
E-mail: mattduncton@yahoo.com
; Tel: +1 917-345-3183
Med. Chem. Commun., 2012,3, 611-619
DOI:
10.1039/C2MD00307D
Received
15 Dec 2011,
Accepted
07 Mar 2012
First published online
28 Mar 2012
2,5-Disubstituted benzoxazole derivatives were evaluated for their ability to inhibit hFAAH. Structure–activity studies indicated that an isoindoline group at the 2-position of the benzoxazole ring gave rise to particularly potent inhibitors. Further refinement resulted in compounds, such as 50, with low nanomolar potencies against hFAAH. Preliminary biochemical experiments revealed that model benzoxazole FAAH inhibitors inhibited the enzyme in a manner consistent with a reversible mechanism. Additionally, the species dependency of FAAH inhibition was measured. Of the species tested, inhibition of rabbit FAAH, but not rat and guinea pig FAAH, appeared to show close alignment to human FAAH. These results may suggest similarities between the active sites of the FAAH enzyme for these two species, and may also suggest that rabbit could be a viable species with which to conduct preclinical testing with benzoxazole FAAH inhibitors.
Fetching data from CrossRef. This may take some time to load.